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research is needed to understand how differences in the characteristics of the 
patients treated with PR+T versus PR impact on treatment adherence and 
hospitalization patterns observed.  
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EPIDEMIOLOGIC TRANSITION OF HEPATITIS A IN SIX COUNTRIES AND 
IMPLICATIONS FOR VACCINATION POLICY: DATA FROM A SYSTEMATIC 
LITERATURE REVIEW  
Durden E1, Maiese BA2, Foley K2 
1Truven Health, Austin, TX, USA, 2Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To evaluate hepatitis A (HAV) endemicity in six countries via 
systematic review of published literature. The countries represent varying 
seroprevalence (different stages of the HAV epidemiologic transition), stages of 
vaccine consideration, and face different circumstances that may affect vaccine 
adoption. METHODS: Articles published from 1990 to October 2011 were 
identified through a number of article search engines, including PubMed®. Search 
terms were “Hepatitis A” and [Country]. Reference lists of identified articles were 
reviewed for relevant articles published prior to 1990. A supplementary Internet 
search identified additional information not indexed in the reviewed search 
engines. Articles were excluded if they focused on the biological mechanisms of 
hepatitis A, were non-human studies, vaccine trial results, case studies or 
opinion pieces. RESULTS: A total of 797 articles were identified. After exclusions, 
the number of articles reviewed were: Chile, 33; India, 80; Mexico, 25; Russia, 38; 
South Korea, 75; and Taiwan, 65. India is still considered to have high HAV 
endemicity, while Chile and Mexico are intermediate, and Korea, Russia, and 
Taiwan are low. The timeframe of available data differed greatly by country and 
often region/city within a country, with some regions only having data as recent 
as five (in Mexico, Taiwan) or ten (in Chile, India, Russia) years ago. Data 
supporting the HAV epidemiologic transition varied by country, and it was often 
unclear at which point the country transitioned to a lower endemicity category, 
if at all. Hepatitis A incidence data were sparse for some countries, and recent 
outbreaks were reported in Korea and Taiwan. CONCLUSIONS: Data gaps, 
including determination of the HAV epidemiologic transition, exist to some 
extent in all the countries studied. Filling these data gaps to enhance knowledge 
of the burden of HAV will assist countries in decision-making regarding vaccine 
adoption.  
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THE IMPACT OF PRICING METHODOLOGIES ON COMMUNITY ACQUIRED 
PNEUMONIA (CAP) DRUGS IN BRAZIL  
Stevens CA1, Miller KL1, Rossi C2 
1PAREXEL Consulting, Waltham, MA, USA, 2PAREXEL INTERNATIONAL, Uxbridge, UK  
OBJECTIVES: Pharmaceutical spending in Brazil represents approximately 11% of 
its total Gross Domestic Product (GDP). Sales of generics represented 17.2% of the 
pharmacy sector by value and 21.3% by volume in 2010, and are expected to grow 
at a higher rate than the overall pharmacy market. This study looks at how the 
increase in generics use, along with reference price controls, may impact access 
to newly approved Community Acquired Pneumonia (CAP) drugs. METHODS: An 
array of published data such as pricing process, current policies, sector-specific 
research articles contributed towards a framework to understand the key factors 
affecting access to CAPs drugs, were gathered. The data then informed a 
telephone survey of national and regional health care stakeholders (N=5). 
RESULTS: Findings show that in Brazil: 1) New CAP products are placed in 1 of 2 
product categories based on comparisons to comparator agents; 2) Category I 
products are considered to be better than the comparator and can charge a 
premium price; 3) The price cannot exceed the lowest price of 9 reference 
countries, which are Australia, Canada, Spain, USA, France, Greece, Italy, New 
Zealand and Portugal; 4) Category II products do not demonstrate a benefit over 
the comparator and the price is based on a cost-minimization analysis; and 5) 
There are no national guidelines for treating CAP. CONCLUSIONS: Drugs used to 
treat CAP are compared to comparator agents based on clinical efficacy and 
overall patient benefit. This will determine placement in a product category that 
will drive pricing. Pharmaceutical companies developing new antibiotics to treat 
CAP must 1) consider launch sequence/timing in reference price countries; 2) 
assess the impact of price based on product category placement; 3) demonstrate 
cost–effectiveness of the drug; and 4) determine whether a new product will 
provide a benefit over comparator agents.  
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HIV LABORATORY TESTS USED AS A PROXY FOR MEDICAL VISITS FOR 
DEFINING ENGAGEMENT IN CARE  
Dean B1, Debes R2, Bozzette S3, Buchacz K4, Brooks JT4 
1Cerner Research, Culver City, CA, USA, 2Cerner Corporation, North Kansas City, MO, USA, 
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OBJECTIVES: Attendance at biannual medical visits has been proposed as a 
minimum U.S. standard for adequate engagement in human immunodeficiency 
virus (HIV) care. The U.S. National HIV Surveillance System collects dates of HIV 
laboratory tests but not medical visits, the current metric for determining if a 
patient is engaged in medical care. Using data from the HIV Outpatient Study 
(HOPS), we analyzed how reported laboratory data correlated with actual 
engagement in care. METHODS: The HOPS is an open prospective study of HIV-
infected patients receiving outpatient care. The dataset included dates for 
laboratory measurements and medical encounters. We included patients with at 
least one HIV laboratory test and one medical visit during 2010-2011. An HIV 
laboratory test was associated with a medical visit if it occurred within 3 weeks 
of the visit. We assessed the predictive value of HIV laboratory tests as a proxy 
for adequate engagement in clinical care, defined as having had ≥2 HIV 
laboratory tests within 1 year where the tests were performed ≥90 days apart. 
RESULTS: A total of 10,301 HIV laboratory tests were recorded from among 2,895 
patients. Most (75%) laboratory tests were measured on the same day as a 
clinical visit; 90% were within ±3 weeks. The prevalence of adequate engagement 
in clinical care in HOPS based on medical visits was 89%. Using HIV laboratory 
tests to measure engagement had sensitivity of 85%, specificity of 87%, and 
positive and negative predictive values of 98% and 42%. Of the 21.4% of persons 
classified as not engaged in care by the proxy measure, 58% were actually 
engaged. CONCLUSIONS: Using ≥2 documented HIV laboratory tests measured 
≥90 days apart reliably classified persons as engaged in care. However, more 
than half of persons not meeting the proxy definition were misclassified as not 
adequately engaged in care.  
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ANTIFUNGAL TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH A 
BLOOD CULTURE POSITIVE FOR CANDIDA AND WITH SEPSIS OR CRITICAL 
ILLNESS  
Wade RL1, Chaudhari P2, Yu HT1, Nathanson BH3, Hays HD1, Yi J1, Horn D4 
1Cerner Research, Culver City, CA, USA, 2Astellas Pharma US, Northbrook, IL, USA, 3OptiStatim 
LLC, Longmeadow, MA, USA, 4David Horn, LLC, Doylestown, PA, USA  
OBJECTIVES: Timely initiation of antifungal therapy in septic or critically ill 
(CrILL) patients with candidemia is crucial, and real-world treatment and 
outcomes data in such patients are limited. We examined treatment patterns 
and outcomes for septic/CrILL inpatients with candidemia. METHODS: This 
retrospective study of electronic health record data from 7/2005-3/2012 used 
Cerner’s Health Facts. Adult inpatients with ≥1 blood culture positive for any 
species of Candidaand sepsis/CrILL were studied. CrILL was defined as ≥1 organ 
system dysfunction plus intensive care unit exposure. Timing of initial 
antifungal therapy relative to the index blood culture draw (BCx), length-of-stay 
following first antifungal order (AF-LOS), mortality, and measures of resource 
utilization were explored using descriptive statistics. Chi-square was used for 
proportional, and t-test for continuous data comparisons. RESULTS: Of 1,288 
candidemia patients with sepsis/CrILL, 266 initiated antifungal therapy prior to 
BCx, 150 within 24h of BCx, 590 after 24h, and 282 received no antifungal 
therapy. The mortality rates were 39.9%, 30.7%, 29.7%, and 51.1%, respectively. 
(P<0.001). Initial antifungal therapies in those treated ≤24h of BCx were: 
fluconazole in 54.0%, echinocandin in 39.3%, other azoles in 3.3%, and 
amphotericin B in 3.3%. In patients treated within 24h after BCx with fluconazole 
(n=81) or echinocandin (n=59), occurrence of bacteremia was high (71% vs. 75%); 
echinocandin patients had a higher mean number of organ system dysfunctions 
than fluconazole patients (1.8 vs. 1.5, P=0.04). In the ≤24h treated groups, AF-LOS 
(fluconazole 20.8, echinocandin 22.1 days; P=0.63) and mortality (fluconazole 
25.9%, echinocandin 32.2%; P=0.42) was similar, as were total charges 
(approximately US$76,000). CONCLUSIONS: A large proportion of inpatients with 
candidemia and sepsis/CrILL failed to receive antifungal therapy within 24h of 
the first positive BCx, with an adverse mortality effect. Nonetheless, patients 
treated within 24h have high mortality and resource utilization.  
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TREATMENT PATTERNS IN PEDIATRIC ANTIBIOTIC FORMULATIONS:  
AN ANALYSIS OF THE RAMQ DATABASE  
Lachaine J1, Beauchemin C1, Lapierre ME1, Snow LA2 
1University of Montreal, Montreal, QC, Canada, 2Abbott, St-Laurent, QC, Canada  
OBJECTIVES: In clinical practice, the taste of liquid pediatric antibiotics may 
contribute to treatment acceptance and compliance. The purpose of this study 
was to analyze treatment patterns and persistence with liquid pediatric 
antibiotics, in a real life setting, using the RAMQ database. METHODS: Selected 
patients were < than 20 years old and were covered by the Quebec provincial 
drug reimbursement program (RAMQ). They were prescribed a liquid pediatric 
antibiotic (branded or generic formulation) during the period from July 2008 to 
April 2011 at least once. The analyses evaluated patients and treatment 
characteristics and patterns in terms of short-term (30 days or less) and long-
term (> than 30 days) repeated use. RESULTS: Data were available for a sample of 
67,727 patients who used an antibiotic of interest. The average age of the study 
population was 4.7 years (SD=3.5) and 89.9% were < than 10 years old. The 
proportion of boys versus girls was similar (51.2% versus 48.8%, respectively). 
Amoxicillin trihydrate and macrolides, clarithromycin and azithromycin were 
most often used (49.3% and 33.0%, respectively). About 55.4% of children received 
more than one antibiotic during the study period. Among children who received 
a second antibiotic, about 22.5% required it within 30 days following treatment 
initiation. In the short-term, the need for a second antibiotic was more frequent 
when cephalosporin was the initial treatment. In the long-term, when the initial 
treatment was amoxicillin or a macrolide, subsequent antibiotics were more 
likely to be the same as the first antibiotic. CONCLUSIONS: Many children will 
require more than one antibiotic treatment during their childhood. Several 
factors may contribute to short-term acceptance and compliance of the initial 
antibiotic, one of which may be taste. The better the acceptance and compliance 
to the initial antibiotic, the more likely the same antibiotic will be used for 
subsequent treatments.  
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OBJECTIVES: To evaluate the relative likelihood of severe cutaneous reactions 
(Steven-Johnson Syndrome, toxic epidermal necrolysis), aseptic meningitis, and 
organ dysfunction (pancreatitis, hepatotoxicity) associated with antiepileptic 
drugs (AEDS) in children (aged 2-18 years) as compared to adults (aged 19+) with 
epilepsy. METHODS: This retrospective cohort study analyzed patients in a large 
nationally representative administrative claims database between 2006 and 2011. 
The sample consisted of Medicaid, Medicare, and Commercial patients with a 
diagnosis of epilepsy (ICD-9-CM 345.X) who were continuously enrolled with 
pharmacy benefits for 6-months and had no prior AEDS fills (new users). 
Multivariate analysis (logistic regression) was used to follow eligible patients 
from index date to first adverse event or up to six months after AED initiation. 
RESULTS: The study population included 1,803,871 new users of AEDS. Children 
comprised 7.9% (N=142,874, female=50.7%, age=12.4 [± 4.7]) and adults 92.1% 
(N=1,660,997, female=64.6%, age=52.8 [± 17.7]). Compared to adults, children were 
significantly less likely to experience organ dysfunction (OR=0.228, 95% CI: 0.20-
0.26, p<0.0001), but more likely to have severe cutaneous reactions (OR=1.19, 95% 
CI: 1.14-1.25, p<0.0001) after controlling for potential confounders (gender, 
region, type of medication). There was no significant age effect on risk of aseptic 
meningitis. Female adults had a statistically lower likelihood of organ 
dysfunction compared to males (OR=0.75, 95% CI: 0.72-0.77, p<0.0001), but there 
was no gender effect for risk of organ dysfunction in children. Females in both 
groups had a higher likelihood of developing cutaneous reactions compared to 
males (adults: OR=1.28, 95% CI: 1.25-1.31, p<0.0001; children: OR=1.20, 95% CI: 
1.15-1.26, p<0.0001). CONCLUSIONS: Adverse effects resulting from treatment 
with AEDS are an important consideration in evaluating epilepsy treatment 
options. This study provides new information about the comparative risks of 
AEDS that can be used to guide optimal prescribing practices for patients with 
epilepsy.  
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DISEASE: EVIDENCE FROM A LARGE EMPLOYER POPULATION  
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OBJECTIVES: To assess the comparative risk of adverse effects (AEs) across 
common treatment regimens for Parkinson’s disease (PD) in a large, real-world 
population. METHODS: Retrospective analyses were conducted using the 
MarketScan database, an employer-based source of inpatient, outpatient, and 
pharmacy claims for >30 million lives. Patients had ≥1 PD diagnosis (ICD-9-CM 
332.0) during 2000-2011 and ≥1 of the following anti-PD regimens: levodopa 
monotherapy (L-dopa), dopamine agonist monotherapy (DA), anticholinergic 
monotherapy (AC), L-dopa+DA, MAOB-inhibitor monotherapy (MAOB),  
L-dopa+COMT-inhibitor (L-dopa+COMT), L-dopa+AC, L-dopa+MAOB, or 
amantadine monotherapy (AMTD). Index groups were assigned based on first 
regimen exposed to. Patients had ≥6 months pre-index plan enrollment and were 
followed from index until AE or earliest of new regimen start, disenrollment, or 
database end. Cox models were estimated for each AE with covariates for index 
regimen (reference: MAOB), demographics, and pre-index comorbidities and AEs. 
RESULTS: 41,652 patients met the inclusion criteria (mean[SD] age: 73.4[11.0] 
years, 57.5% male). Index regimen distribution was: L-dopa (n=28,249), DA 
(n=7,775), AC (n=1,496), L-dopa+DA (n=578), MAOB (n=1,498), L-dopa+COMT 
(n=343), L-dopa+AC (n=106), L-dopa+MAOB (n=198), AMTD (n=1,409). AC,  
L-dopa+AC, and AMTD carried increased dyskinesia risk versus MAOB (hazard 
ratios (HRs) [95% CIs]: 2.1[1.8-2.5 ], 1.7[1.1-2.7], and 1.9[1.6-2.2], respectively).  
L-dopa+DA and L-dopa+MAOB had increased risk of orthostatic hypotension 
(HRs: 2.2[1.4-3.5] and 2.5[1.3-5.0]). L-dopa+DA carried the highest edema risk (HR: 
2.1[1.6-2.6]). L-dopa+DA and AMTD had increased risk of hallucinations (HRs: 
2.6[1.3-5.1] and 3.0[1.8-4.8]). For 6 of 9 AEs examined, L-dopa+DA had 
significantly (p<0.05) increased risk versus MAOB; in 4 of these (orthostatic 
hypotension, edema, nausea, hallucinations), L-dopa+DA carried the highest or 
second highest HR versus MAOB amongst all regimens examined. 
CONCLUSIONS: Treatments with high dopaminergic levels (L-dopa+DA) 
generally carried increased AE risk versus MAOB monotherapy. However, other 
dopamine-containing and non-dopaminergic regimens also carried increased AE 
risk versus MAOB. These findings highlight practical challenges presented by 
current PD treatments.  
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OBJECTIVES: To evaluate incidence of adverse effects (AEs) commonly associated 
with Parkinson’s disease (PD) and its treatments in a large, real-world 
population. METHODS: Retrospective analyses were conducted using the 
MarketScan database, an employer-based sourced of inpatient, outpatient, and 
pharmacy claims for >30 million lives (2000–2011). Inclusion criteria were ≥1 PD 
diagnosis (ICD-9-CM 332.0) and ≥30 days exposure to ≥1 of the following 
regimens: levodopa monotherapy (L-dopa), dopamine agonist monotherapy (DA), 
anticholinergic monotherapy (AC), L-dopa+DA, MAOB-inhibitor monotherapy 
(MAOB), L-dopa+COMT-inhibitor (L-dopa+COMT), L-dopa+AC, L-dopa+MAOB, 
amantadine monotherapy (AMTD). Patients were followed on AEs (defined by 
ICD-9-CM diagnoses) over all observed regimen exposures. Analyses were 
descriptive. RESULTS: In total, 87,373 patients were identified for inclusion 
(mean [SD] age 72.8 [10.9] years, 56.8% male). L-dopa was the largest cumulative 
exposure (80,246 person-years [PYs]), followed by L-dopa+DA (19,871 PYs) and DA 
(18,324 PYs). Dyskinesia incidence varied by treatment, ranging from 68/1,000 
PYs for L-dopa+MAOB to 492/1,000 PYs for AC. Orthostatic hypotension was 
higher in 5 of the 6 dopamine-containing regimens (64, 47, 45, 31, 25 per 1,000 
PYs for L-dopa+COMT, L-dopa+MOAB, L-dopa, L-dopa+DA, and DA, respectively) 
versus 2 of the 3 non-dopaminergic regimens (18, 19, 32 per 1,000 PYs for AC, 
MAOB, and AMTD). Edema incidence was highest during DA (215/1,000 PYs) and 
L-dopa+DA (192/1,000 PYs) exposures. Somnolence was highest, by far, during 
DA exposure (201 per 1,000 PYs); L-dopa+DA had the next highest somnolence 
incidence (115 per 1,000 PYs). Incidence of psychoses was high for all regimens 
(range: 202/1,000 PYs for L-dopa+MAOB to 3,500/1,000 PYs for AC). Abnormal 
dreaming/sleep attacks and impulse control disorders were not observed in this 
population, indicating a lack of coding for these conditions in routine practice. 
CONCLUSIONS: AE incidence during anti-PD treatment exposure varies by 
specific regimen. Some AEs, such as orthostatic hypotension, appear to be lower 
in non-dopaminergic monotherapies.  
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OBJECTIVES: To determine the frequency and economic impact of comorbid 
cardiac conditions among hospitalizations of patients with a diagnosis  
of multiple sclerosis (MS). METHODS: A retrospective analysis was conducted 
using the National Inpatient Sample (NIS), Healthcare Cost and Utilization 
Project, Agency for Healthcare Research and Quality. All hospital discharges  
with an MS diagnosis (ICD-9 CM 340.xx) from 1/1/2009 to 12/31/2009 were 
identified. Two cohorts were defined based on the presence or absence of at least 
one cardiac condition using ICD-9-CM codes: myocardial infarction (410.xx), 
ischemic disease (411.xx), angina (413.xx), occlusion of cerebral arteries (434.xx), 
acute cardiovascular disease (436.xx), cerebral ischemia (435.xx), and heart 
failure (428.xx). Total mean charges were converted to costs using NIS 2009 cost-
to-charge ratios. Total costs per discharge were compared between cohorts while 
controlling for demographics, number of chronic comorbidities, and length  
of stay (LOS). Descriptive statistics, t tests, and chi square tests were conducted 
where appropriate, and regression models were employed for cost comparisons. 
An incremental cost effectiveness ratio (ICER) was calculated for the cost per 
additional hospital day. RESULTS: A total of 27,463 discharges with a diagnosis of 
MS were identified, and 9.1% (n=2,522) had at least one cardiac comorbidity. The 
sample was 70% female with a mean age of 53.5 years. MS discharges with a 
cardiac condition were for patients with a significantly higher mean age (62.5 vs 
50.5 years, P<0.0001), more chronic comorbidities (7.8 vs 4.7 conditions, P<0.0001), 
and a longer LOS (6.4 vs 5.2 days, P<0.0001). The cost of hospitalization  
was significantly higher for MS discharges with a cardiac comorbidity after 
controlling for confounders ($16,752 vs $10,549, P<0.0001). The incremental  
cost per hospital day was $5,375 for discharges with a cardiac condition. 
CONCLUSIONS: Cardiac comorbidities are prevalent among MS discharges  
and are associated with higher costs than discharges without a cardiac 
comorbidity.  
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OBJECTIVES: To identify clinical and demographic predictors of urgent health 
care services utilization in monotherapy-treated patients with epilepsy. 
METHODS: Patients aged 18-64 years with a primary or secondary diagnosis of 
epilepsy and >1 prescription claim for an antiepileptic drug (AED) pre-index  
were included. Innovus Invision™ Data Mart insurance claims from January 1, 
2007 to September 30, 2010 were retrospectively analyzed. The primary outcome 
was incidence of seizures defined as an occurrence of an emergency room visit, 
ambulance service use or hospitalization with a primary or secondary diagnosis 
of epilepsy during the 1-year follow-up. Predictor variables included AED 
adherence, general comorbidity, any mental health comorbidity, evidence  
of a prior seizure, type of epilepsy diagnosis, presence of AED-interacting 
medications and any bioequivalent AED switch. The covariates included  
age, gender and geographic region of residence. RESULTS: The overall incidence 
of post-index seizures in the 1-year follow-up for four monotherapy cohorts 
combined was 5.3 % (n=166/3140). The combined cohort analysis demonstrated 
that pre-index seizures (odds ratio [OR] = 4.28; 95% CI, 2.81-6.53), any mental 
health comorbidity ([OR] = 3.41; 95% CI, 2.10-5.54), Charlson Comorbidity Index ≥1 
([OR] = 2.88; 95% CI, 1.96-4.24) and monotherapy with levetiracetam ([OR] = 1.54; 
95% CI, 1.03-2.31) were significant predictors of seizure recurrence. Among 
covariates, only geographic region was a significant predictor, with patients 
residing in the Northeast U.S. having higher odds of post-index seizure ([OR] = 
1.92; 95% CI, 1.19-3.10), while controlling for clinical, medication and 
demographic characteristics. A bioequivalent AED switch, type of epilepsy 
diagnosis, AED adherence and presence of interacting medications were  
not significant predictors of seizure recurrence (p>0.05). CONCLUSIONS: Results 
indicate that epilepsy patients with comorbid conditions (both mental  
and somatic diseases), as well as patients who may have initially been  
unstable (with previous seizure occurrences) were more likely to experience 
seizures.  
